Kestra Medical Technologies (NASDAQ:KMTS) Insider Timothy Moran Sells 2,380 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Timothy Moran sold 2,380 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $23.76, for a total transaction of $56,548.80. Following the completion of the transaction, the insider directly owned 66,345 shares of the company’s stock, valued at approximately $1,576,357.20. This trade represents a 3.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Performance

KMTS stock traded up $1.16 during midday trading on Monday, reaching $23.99. 373,728 shares of the company’s stock traded hands, compared to its average volume of 404,856. The firm has a market capitalization of $1.41 billion, a PE ratio of -9.91 and a beta of 0.58. The company has a 50-day moving average price of $22.62 and a two-hundred day moving average price of $22.48. Kestra Medical Technologies, Ltd. has a 52 week low of $14.10 and a 52 week high of $30.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The company had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. As a group, equities analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of KMTS. California State Teachers Retirement System raised its stake in Kestra Medical Technologies by 39.2% in the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock valued at $555,000 after purchasing an additional 7,844 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Kestra Medical Technologies by 6.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock worth $1,844,000 after buying an additional 5,731 shares in the last quarter. Quantinno Capital Management LP bought a new position in shares of Kestra Medical Technologies in the 1st quarter worth $431,000. Sei Investments Co. raised its position in shares of Kestra Medical Technologies by 22.6% during the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after buying an additional 43,753 shares in the last quarter. Finally, Spartan Wealth Advisory Services LLC bought a new stake in shares of Kestra Medical Technologies during the 1st quarter worth $603,000.

Analysts Set New Price Targets

KMTS has been the subject of a number of recent analyst reports. Wall Street Zen lowered Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. The Goldman Sachs Group cut their price objective on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Weiss Ratings lowered shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. Finally, Oppenheimer began coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating on the stock. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $27.83.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.